NCT06798363

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma： a Prospective Study

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 1 Month – 4 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).

Detailed description

Infantile hemangioma (IH) is the most common benign tumor in infants, with an estimated prevalence of 4%-5%. Although most IH resolves over time without serious sequelae, a significant proportion can lead to serious complications such as ulcers. Propranolol is considered to be an effective treatment modality for ulceration IH, and there are retrospective studies suggesting that starting treatment at a low dose is safe and effective. However, due to the lack of prospective study, the effectiveness of different doses of propranolol for initiating treatment of ulceration IH is unknown. Therefore, a prospective study of ulceration IHs in Chinese children was conducted to clarify its efficacy.

Conditions

• Infantile Hemangioma

Interventions

Type	Name	Description
DRUG	propranolol	different dose

Timeline

• Start date: 2025-05-02
• Primary completion: 2026-06-30
• Completion: 2026-08-01
• First posted: 2025-01-29
• Last updated: 2026-03-16

Locations

1 site across 1 country: China